Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Inspire Medical Systems approaches its November 2 earnings report with short sellers still in control, an analyst community more divided than the consensus numbers suggest, and options traders who have shifted decisively away from the defensive posture they held just two weeks ago.
Short interest continued to grind higher this week. Bears added a further 3.5% to their positions on Tuesday, taking the total to 15.1% of free float, roughly 4.38 million shares. That is up 2.6% on the week and 5.1% over the past month, building on the pattern noted in the previous note. The pace of accumulation has slowed from the sharp 8.5% weekly move recorded last week, but direction has not changed. Importantly, the lending market remains loose enough to absorb further short demand with minimal friction. Availability tightened from around 778% to 576% on the week, still meaning there are more than five shares available for every one already borrowed. Cost to borrow has actually fallen sharply, down 43% on the week to just 0.29%, after spiking to 0.51% in early October. Shorts can add here cheaply.
The options market has flipped since the previous note flagged call dominance as a contrarian angle. The put/call ratio remains call-heavy at 0.54, but that reading now sits nearly a full standard deviation below its 20-day average of 0.80. Two weeks ago, the PCR was running above 1.20, reflecting heavy demand for downside protection. That defensive hedging has unwound quickly. The shift has coincided with the stock recovering 1% on the week to $68.86, even after a 3.7% drop on Tuesday, and a broader pivot among at least some on the Street toward a higher price range.
The analyst picture is the most interesting new development this week. Truist Securities raised its price target on INSP from $62 to $78 today while maintaining a Hold rating, a signal that even a cautious-rated firm sees more value at these levels after the stock's 24% year-to-date decline. Barclays, which initiated at Underweight with a $65 target last week, sits on the other side. The mean analyst target is $66.13, marginally below the current price of $68.86, which tells a less optimistic story than the Truist move implies. Bulls can point to a $97 target from Freedom Capital Markets and an $85 Outperform from Oppenheimer. Bears note that JPMorgan holds at Neutral with a $60 target and that Barclays opened its coverage with outright bearish conviction. The EPS momentum factor scores are strikingly split: 90-day EPS momentum ranks in the 96th percentile, but the 12-month forward EPS year-on-year growth rank is in the bottom 4% of the universe. The Street is arguing about whether the guidance cut is a floor or a ceiling.
The ownership register adds a notable structural fact. BlackRock built its stake to 16.4% of shares, adding almost 1.2 million shares in the latest reported period. Soleus Capital and AQR both appear in the top holders as relatively recent entrants, each with last-change figures representing a full new position built in the period to June. Against that, FMR (Fidelity) cut its disclosed stake from 8.3% to 2.5%, and Marc Stad exited entirely from 8.0%, both through Schedule 13G/A amendments filed in late 2025. Stakes are as last disclosed around the 5% threshold and holders dropping below 5% may not file again, so the current distribution of the remaining float is less clear than the top-line figures suggest.
Earnings history gives the clearest picture of what November 2 could mean for positioning. The August 2026 print produced a 15% one-day gain and a 13% five-day gain. The print before that delivered 28% on the day. Short sellers sitting at 15% of float heading into a stock with that reaction history are taking on meaningful event risk, and the falling cost to borrow suggests the market is not pricing in an imminent squeeze. What to watch is whether short interest continues to build through the final two weeks before the print, and whether the call-dominated options positioning remains in place or reverts toward the defensive hedging seen in late September.
See the live data behind this article on ORTEX.
Open INSP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
